Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
Bearish
-50.0
HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China. Sciwind Biosciences will remain the Marketing Authorization Holder and will be responsible for research and development, registration, manufacturing, and supply of the product. Under the terms of the agreement, Sciwind Biosciences is eligible to receive up to $495M in upfront, regulatory and sales mileston
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
